ReviewFrontiers in nutrition2026
Targeting cancer hallmarks using resveratrol: isolation, formulation, and mechanisms of action.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic Biological Insights into the Effects of Resveratrol and Nano-Resveratrol on EAT-Induced Hepatorenal Damage.Nutrients · 2026Article
- Hybrid Drug Delivery System Designed from Spatiotemporal Hierarchical Controlled-Release Strategy Co-Delivering Rutin and Resveratrol for Coordinated Anti-Tumor Immunotherapy.Pharmaceutics · 2026Article
- Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products, particularly medicinal plants, play a crucial role in combating cancer and developing new treatments due to their unique properties, such as diverse chemical structures, low toxicity, and the ability to target various types of cancer. They offer a promising approach for the treatment and prevention of certain cancers. Resveratrol, a non-flavonoid polyphenolic compound found in several plants, has demonstrated beneficial effects on various diseases, including cancer, as evidenced by numerous studies. It may also help address multiple cancers by influencing their growth and metastasis. One proposed mechanism is that resveratrol reduces reactive oxygen species (ROS) and lipid peroxidation by activating the JNK/c-JUN signaling pathway, which enhances the expression of antioxidant enzymes. Additionally, resveratrol has been shown to regulate cell proliferation by suppressing the PI3K/Akt pathway and activating the SIRT1 pathway. Other mechanisms include the inhibition of NF-κB activation and the downregulation of downstream proteins such as MMP-9, CXCR4, and FAK, which are known to facilitate metastasis. Furthermore, resveratrol inhibits Akt phosphorylation, and inhibition of PI3K or mTOR mimics its effects on glucose uptake. This review discusses these mechanisms, emphasizing the anticancer properties of resveratrol and its role in various aspects of cancer, supported by research on the compound's formulation and clinical studies involving this natural agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.